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A B S T R A C T
Methylmalonic acidemia (MMA) is a propionate pathway disorder caused by dysfunction of the mitochondrial
enzyme methylmalonyl-CoA mutase (MMUT). MMUT catalyzes the conversion of methylmalonyl-CoA to suc-
cinyl-CoA, an anaplerotic reaction which feeds into the tricarboxylic acid (TCA) cycle. As part of the pathological
mechanisms of MMA, previous studies have suggested there is decreased TCA activity due to a “toxic inhibition”
of TCA cycle enzymes by MMA related metabolites, in addition to reduced anaplerosis. Here, we have utilized
mitochondria isolated from livers of a mouse model of MMA (Mut-ko/ki) and their littermate controls (Ki/wt) to
examine the amounts and enzyme functions of most of the TCA cycle enzymes. We have performed mRNA
quantification, protein semi-quantitation, and enzyme activity quantification for TCA cycle enzymes in these
samples. Expression profiling showed increased mRNA levels of fumarate hydratase in the Mut-ko/ki samples,
which by contrast had reduced protein levels as detected by immunoblot, while all other mRNA levels were
unaltered. Immunoblotting also revealed decreased protein levels of 2-oxoglutarate dehydrogenase and malate
dehydrogenase 2. Interesting, the decreased protein amount of 2-oxoglutarate dehydrogenase was reflected in
decreased activity for this enzyme while there is a trend towards decreased activity of fumarate hydratase and
malate dehydrogenase 2. Citrate synthase, isocitrate dehydrogenase 2/3, succinyl-CoA synthase, and succinate
dehydrogenase are not statistically different in terms of quantity of enzyme or activity. Finally, we found de-
creased activity when examining the function of methylmalonyl-CoA mutase in series with succinate synthase
and succinate dehydrogenase in the Mut-ko/ki mice compared to their littermate controls, as expected. This
study demonstrates decreased activity of certain TCA cycle enzymes and by corollary decreased TCA cycle
function, but it supports decreased protein quantity rather than “toxic inhibition” as the underlying mechanism
of action.
Summary: Methylmalonic acidemia (MMA) is an inborn metabolic disorder of propionate catabolism. In this
disorder, toxic metabolites are considered to be the major pathogenic mechanism for acute and long-term
complications. However, despite optimized therapies aimed at reducing metabolite levels, patients continue to
suffer from late complications, including metabolic stroke and renal insufficiency. Since the propionate pathway
feeds into the tricarboxylic acid (TCA) cycle, we investigated TCA cycle function in a constitutive MMA mouse
model. We demonstrated decreased amounts of the TCA enzymes, Mdh2 and Ogdh as semi-quantified by im-
munoblot. Enzymatic activity of Ogdh is also decreased in the MMA mouse model compared to controls. Thus,
when the enzyme amounts are decreased, we see the enzymatic activity also decreased to a similar extent for
Ogdh. Further studies to elucidate the structural and/or functional links between the TCA cycle and propionate
pathways might lead to new treatment approaches for MMA patients.
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1. Introduction
Isolated methylmalonic acidemia (MMA, OMIM #251000, 251100,
251110) is a severe inborn error of metabolism caused by dysfunction
of the propionate pathway, involved in the catabolism of odd-chain
fatty acids, valine, isoleucine, methionine, threonine, and cholesterol to
succinyl-CoA, which is subsequently metabolized in the tricarboxylic
acid (TCA) cycle. Isolated MMA is characterized by a defect in con-
version of (D-)methylmalonyl-CoA to succinyl-CoA, due to deficiency of
the methylmalonyl-CoA mutase (MMUT) enzyme (E.C. 5.4.99.2), and
may be caused by mutations in the MMUT gene, mutations in genes
involved in production of its cofactor adenosyl-cobalamin, or mutations
in MCEE (E.C. 5.1.99.1) or succinate synthetase (SUCLG1/SUCLA2),
enzymes directly proximal and distal to MMUT [1,2] (Fig. 1). The pa-
tients who suffer from MMA can present in the neonatal period with
coma and metabolic crisis (including severe metabolic acidosis and
hyperammonemia), and if left untreated, die within the first few days of
life [3,4].
With the establishment of newborn screening, MMA patients can be
detected early and pre-symptomatic treatment can be achieved.
However, despite early intervention, long-term complications are ob-
served in these patients [5,6], including neurologic and neurodeve-
lopmental abnormalities [2,7,8]. Renal insufficiency is also common
among MMA patients and this might lead to end-stage renal disease
[7,9]. The pathophysiology of these late complications is yet to be
elucidated. Previous studies found abnormalities in various metabolic
pathways, such as the electron transport system in mitochondria
[10–12] and amino acid metabolism [13,14]. Mitochondrial dysfunc-
tion and oxidative stress were observed in patients with MMA and was
thought to play important roles in the development of renal compli-
cations [15,16]. Two prominent mechanisms proposed to explain the
long-term complications of MMA include 1) the concept of “toxic me-
tabolites” derived from accumulation of methylmalonyl-CoA and pro-
pionyl-CoA excess interrupting, among other things, TCA enzyme
function [17] and the urea cycle [18] and 2) shortage of TCA cycle
intermediates. Propionyl-CoA itself has been shown to inhibit pyruvate
dehydrogenase complex (PDHc) activity [10], while 2-methylcitrate,
formed by a condensation reaction of propionyl-CoA and oxaloacetate,
can inhibit various enzymes in the TCA cycle, such as, citrate synthase
(CS), isocitrate dehydrogenase (IDH2/3) and the α-ketoglutarate de-
hydrogenase complex (OGDHc) [19]. In general, the toxic intermediate
role in disease pathophysiology predicts abnormalities in dehy-
drogenase activity due to inhibition from toxins. On the other hand,
impaired anaplerosis of the TCA cycle might be due to the decreased
production of succinyl-CoA by MMUT in the propionate pathway, as
well as by formation of 2-methylcitrate, which reduces availability of
oxaloacetate [20,21].
Previously, TCA cycle enzymes have been proposed to work as a
complex, called the “metabolon”, which allows metabolite channeling
[22]. Although more evidence is needed, several studies provide sup-
port for the presence of the TCA cycle metabolon [23,24], as well as
metabolons involved in other human metabolic pathways, including the
initial steps of branched-chain amino acid metabolism [25]. If substrate
channeling, created by the interaction of the enzymes which make up a
metabolon unit, is necessary for effective metabolism, deficiency in the
quantity of one enzyme might affect the function of the others. Since
MMUT is a mitochondrial enzyme immediately proximal to the TCA
cycle, it may function as part of the TCA cycle metabolon. By this hy-
pothesis, pathological mutations in Mmut might affect the structure
and/or function of the proposed TCA cycle metabolon and subsequently
lead to decreased TCA cycle function.
We have used a mouse model of MMA (Mut-ko/ki) which has been
described in Forny et al. [26] to model the human disease. These mice
are genetic hybrids which carry a knock-out allele of the Mmut gene
[27] in combination with the knock-in allele p.M698K, corresponding
to the human p.M700K mutation [26]. Like the human disease, these
mice (Mut-ko/ki) demonstrate elevated methylmalonic acid, propio-
nylcarnitine, and 2-methylcitrate, but retain about 1% enzyme activity
[26].
Here we demonstrate that the protein levels of OGDH, the TCA cycle
enzyme is decreased in Mut-ko/ki livers compared to littermate con-
trols, despite a lack of difference in mRNA levels. Several other TCA
cycle enzymes protein levels are also decreased and these contribute to
decreased specific enzyme and whole pathway activity, as measured in
isolated mitochondria. These data support the finding of decreased TCA
cycle activity in MMA, but suggest this effect may be due to decreased
metabolon function rather than an inhibitory effect of toxic inter-
mediates.
2. Material and methods
2.1. Tissue
Flash frozen livers were taken from methylmalonyl-CoA mutase
knock-out/knock-in (Mut-ko/ki) mice that have been described in
Forny et al. [26]. They are referred to as MMA or Mut-ko/ki, here.
Littermates, which carry one knock-in and one wild-type allele (and
have 50%Mmut expression and normal metabolite levels), were used as
controls (Ctl or ki/wt). Animal experiments were performed in ac-
cordance with policies of the Veterinary Office of the State of Zurich
and Swiss law on animal protection. Animal studies were approved by
the Cantonal Veterinary Office Zurich under license number 202/2014.
All mice were sacrificed between 30 and 40 days of life and were pre-
dominately females.
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Fig. 1. TCA cycle and Propionate Pathway. A diagram of the TCA cycle showing
its intermediates and energy sources. TCA is fed by the propionate pathway,
glycolysis and fatty acid oxidation (via acetyl-CoA) which all help to maintain
TCA intermediates. The propionate pathway is characterized by production of
propionyl-CoA and is involved in metabolism of cholesterol, valine, odd chain
fatty acids, methionine, isoleucine and threonine (c-VOMIT). Mut is the last
step in the propionate pathway and feeds succinyl-CoA into the TCA cycle.
Here, the intermediates and enzymes of interest (boxed and capitalized) are
listed. Two known “toxins”, 2-methylcitrate and 3-hydroxypropionate are also
illustrated. Abbreviations: CS (citrate synthase), aconitase 2 (ACO2), isocitrate
dehydrogenase 2/3 (IDH2/3), 2-oxoglutarate dehydrogenase complex
(OGDHc), succinate synthase (SS), succinyl-CoA synthetase (SCS), methylma-
lonyl-CoA mutase (MUT), propionyl-CoA carboxylase (PCC), c-VOMIT (cho-
lesterol, valine, odd chain fatty acids, methionine, isoleucine, threonine), suc-
cinate dehydrogenase (SDH), fumarate hydratase (FH), malate dehydrogenase 2
(MDH2), 2-methycitrate (2-MC), 3-hydroxypropionic acid (3-OH PA).
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2.2. Mitochondrial isolation
Mitochondria from flash frozen livers of Ctl and Mut-ko/ki mice
were isolated. Briefly, each mouse liver was ground, weighed on ice and
placed in 15mL mitochondrial isolation buffer (5mM Tris-HCl pH 7.2,
250mM sucrose and 1mM EDTA, pH 7.2) and homogenized. The
sample was then centrifuged at 484g for 10min at 4o C and the su-
pernatant collected. The supernatant then underwent centrifugation at
9800g for 10min at 4o C and the pellet was collected. The pellet was re-
suspended in 4mL and transferred to 2 new tubes. The samples were
again centrifuged at 484g for 10min at 4 °C and supernatant collected.
The supernatant then underwent centrifugation again at 9800g for
10min at 4 °C. The pellet was collected and resuspended in mitochon-
drial isolation buffer and centrifuged at 18,000g for 5min at 4o C. The
pellet is mitochondria and can be stored at -80o C. The mitochondrial
pellet was resuspended in extraction buffer (which opens mitochondria)
(5mM Tris-HCl pH 7.2, 250mM sucrose, 1 mM EDTA, 1% IDEPAL, 1
tablet Mini protease inhibitor (Roche) per 10mL, pH to 7.5 with glacial
acetic acid) prior to use in every assay. The protein quantification of
mitochondria was then performed using Pierce™ BCA Protein Assay Kit
(ThermoFisher Scientific).
2.3. Enzymes assay
All TCA enzymes were measured spectrophotometrically (xMark™
Microplate Absorbance Spectrophotometer (Bio-Rad)) using isolated
mitochondria. All measures were done in Kinetic mode at 250C, at the
wavelengths described below for each specific assay, with measure-
ments taken every 20 s for at least 30 cycles unless otherwise specified.
Each individual enzyme assay was performed in triplicate and the re-
sulting enzyme rates averaged. The rate was determined according to
the linear portion of each pattern. Each condition (i.e. Mut-ko/ki versus
ki/wt ctl) was assayed using three separate samples from three separate
animals. Distilled Water (dW) was used as a control substituting for the
enzyme substrate for each reaction in the assays shown in Fig. 2. Re-
action rates were not corrected for dW rates.
2.4. Citrate synthase (Cs) (E.C. 2.3.3.8)
Cs activity was measured by detecting thiobis(2-nitrobezoic acid)
(TNB), a by-product of the reaction between coenzyme A (CoA-SH) and
5,5’dithiobis(2-nitrobenzoic acid) (DTNB) since CoA-SH is released by
the reaction (Suppl. Fig. S1. A.). The assay is started when 1mM ox-
aloacetate is added to 5 μg of mitochondrial samples mixed with reac-
tion buffer (10mM tris-HCl pH 8.0, 0.1mM DTNB, 0.2 mM acetyl Co-A,
0.18% Triton-X). The production of TNB was followed spectro-
photometrically at 412 nm as similarly described in Shephard et al. [28]
measuring every 20 s for 30 cycles. The results were graphed and slope
(which correlates to enzyme rate) was determined. The enzyme activity
was then calculated.
2.5. Isocitrate dehydrogenase 2/3 (Idh2/3) (E.C. 1.1.1.41 and 1.1.1.42)
The activity of Idh2/3 was determined by measuring production of
NADPH at 340 nm (Suppl. Fig. S2 A). The reaction was started by
adding 200 μL of reaction buffer (10mM potassium phosphate pH 7.4,
2mM MgCl2, 1 mM NADP and 5mM isocitrate) to 30 μg of mitochon-
dria [29] and measurements taken every 20 s for 30 cycles. Each ana-
lysis was done in triplicate and the resulting slopes averaged and used
to determine enzyme activity.
2.6. α-Ketoglutarate dehydrogenase complex (Ogdhc))(E.C. 1.2.4.2)
The reaction mixture containing 63mM Tris-HCl pH 7.4, 2mM
MgCl2, 0.63mM potassium-EDTA, 2mM CaCl2, 1 mM DTT, 0.2mM
TTP, 1mM NAD+, 0.3 mM coenzyme A, 0.5% Triton-X was added to
30 μg of mitochondria samples. The reaction started by adding 1mM α-
ketoglutaric acid. The production of NADH was measured spectro-
photometrically at 340 nm [30] and measurements were taken every
20 s for 30 cycles (Suppl. Fig. S3 A). Each analysis was done in triplicate
and the resulting slopes averaged and used to determine enzyme ac-
tivity.
2.7. Succinyl-CoA synthetase (Scs) (E.C. 6.2.1.5 and 6.2.1.4)
The Scs assay was achieved by Succinyl-CoA Synthetase Activity
Colorimetric Assay Kit (BioVision Inc.). The reaction buffer was mixed
according to the manufacturer's instructions and 20 μg of mitochondrial
samples were added to start the reaction and followed as instructed by
the assay kit (Suppl. Fig. S4 A). Each analysis was done in triplicate and
the resulting slopes averaged and used to determine enzyme activity.
2.8. Succinate dehydrogenase (Sdh) (E.C. 1.3.5.1)
The activity of Sdh was determined based on its ability to reduce
DCPIP, an artificial electron acceptor (Suppl. Fig. S5 A). The reaction
mixture of 50mM potassium phosphate pH 7.4, 0.14mM DCPIP,
0.1 mM duroquinone, 0.8 mM PMS, 8 uM rotenone, and 12mM succi-
nate was added to 30 μg of mitochondrial samples. The assay was
measured at 600 nm [31,32] every 20 s for 30 cycles. Each analysis was
done in triplicate and the resulting slopes averaged and used to de-
termine enzyme activity.
2.9. Fumarate hydratase (Fh)
The reverse reaction of Fh starts with malate and generates fuma-
rate which was detected at OD 250 nm (Suppl. Fig. S6 A). To start the
reaction, mitochondria (30 μg) were placed in reaction buffer (50mM
Na2HPO4, 0.1% BSA, and 50mM malic acid). The reaction was fol-
lowed spectrophotometrically at 250 nm and measurements are taken
every 20 s for 30 cycles [33]. Each analysis was done in triplicate and
the resulting slopes averaged and used to determine enzyme activity.
2.10. Malate dehydrogenase 2 (Mdh2) (E.C.1.1.1.37)
The reverse function of Mdh2 was measured by following the de-
crease of NADH at OD 340 nm (Suppl. Fig. S7 A). The reaction mixture
contained 100mM potassium phosphate, 1mM NADH, and, 2mM ox-
aloacetate. The reaction was started by adding 200 μL of reaction
mixture to 30 μg of mitochondrial samples [34] and measured at
340 nm every 15 s for 30 cycles. Each analysis was done in triplicate
and resulting slopes (correlate with enzyme activity) were averaged.
2.11. Mut-Ss-Sdh coupled assay
Mmut, succinate synthase (Ss) and Sdh were assayed in series in a
coupled assay (Suppl. Fig. S10 A). Reaction buffer containing 50mM
potassium phosphate pH 7.4, 10mM MgCl2, 0.14mM DCPIP, 0.1 mM
duroquinone, 0.8mM PMS, 8 uM rotenone, 0.01mM AdoCbl, and 1mM
methylmalonyl-CoA was added to 30 μg of mitochondrial samples. The
reduction of DCPIP was followed spectrophotometrically at 600 nm
[31,35]). Measurements were taken every 20 s for 30 cycles. The slope
of the line created correlates with the serial enzyme activity. Since the
measure is from SDH there is residual activity as seen in the control
with no methylmalonyl-CoA, but with all the other components of the
reaction buffer.
2.12. Immunoblotting
For each sample, 5 μg protein (in mitochondrial lysate) was loaded
into an Any kD™ Mini-PROTEAN® (Bio-rad) acrylamide gel. The pri-
mary antibodies used for probing each enzyme were anti-Cs (ab96600,
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Abcam, 1:5000), anti-Idh2 (ab94359, Abcam, 1:500), anti-Ogdh
(ab137773, Abcam, 1:5000), anti-Suclg2 (ab187996, Abcam, 1:5000),
anti-Sdha1 (ab139181, Abcam, 1:2000), anti-Fh (ab95947, Abcam,
1:2000), anti-Mdh2 (ab96193, Abcam, 1:1000), anti-Pcca (A304-324A,
Bethyl, 1:5000), anti-Vdac1 (ab15895, Abcam, 1:2000). Anti-Pccb
(1:4000) and anti-Mut (1:5000), were made by Bio-Synthesis,
Lewisville, TX, USA against peptides containing amino acids
NH2-CRLRATFAGLYSSLDVGEEGDQ-OH for Pccb and
NH2-CPEWAALAKKQLKGKNPED-OH for Mut. Chicken anti-Rabbit IgG-
HRP (sc-2955, Santa Cruz, 1:2000) was used as secondary antibody.
Protein quantification was performed by measuring the amount of ab-
sorbance on a ChemiDoc™ MP Imaging System (170–8280; Bio-Rad)
using Image Lab Software 5.1 by BioRad.
All immunoblot normalizations were performed using Vdac1, a
mitochondrial membrane voltage dependent anion channel which is
independent of the propionate and TCA cycle pathways, as loading
control.
Enzyme rates calculation:
= =Enzyme rate Unit/(m)g protein µmol min (m)g1 1
The slope of the measured analyte on the spectrophotometer is
equal to the rate of the conversion (measured in units * sec−1) and so
slope *(60 s) * min−1 * mg−1= slope (60) * min−1 *(amount of mi-
tochondrial protein or total protein used for assay=mg−1) is equal to
the enzyme rate. All enzymatic figures use enzyme rate measured as
pmol * sec−1 in which the amount of protein used is the amount of
protein measured in mitochondrial lysate.
2.13. RNA isolation and expression profiling
RNA was isolated from two additional livers from each of the Mut-
ko/ki and Ctl mice using the mirVANA isolation kit (Ambion, Life
technologies) following manufacturer's instructions. RNA was analyzed
for quality by electrophenogram and Northern blot prior to use to
confirm that the RNA was of good quality as is standard in our in-
stitution. Expression was determined using the Clariom S mouse Array
(Applied Biosystems). Fold change, p-values (with Bonferroni correc-
tion) and FDR p values were determined for 29, 129 probes. Data are all
loaded under GEO number: GSE121060.
2.14. Statistics
All enzyme assays were done in triplicates in livers isolated from
three separate animals (3 from Mut-ki/ko and 3 from Ctl animals).
Means and standard deviations were calculated for all assays. Student t-
tests were used to determine statistical significance (p < .05). Linear
regression was done to evaluate the ratio of enyzme activity versus the
normalized quantity of enzyme detected by immunoblot. Calculations
were performed using GraphPad Prism v8.
3. Results
Here, we set out to define the effect of loss of Mmut on TCA cycle
proteins/function. We used flash frozen liver taken from mice with a
defect in methylmalonyl-CoA mutase (Mut-ko/ki, MMA) and compared
them to littermate controls (ki/wt, Ctl).
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Fig. 2. Immunoblots and quantitation bar graphs of the TCA cycle enzyme amounts from three separate Mut-ko/ki mice and three separate Ctl mice. Primary
antibody used is listed on the left by each blot. These blots were semi-quantitated using the ChemiDoc™ MP Imaging System (170–8280; Bio-Rad) and Image Lab
Software 5.1 by BioRad and listed in Table 3. No manipulation of the original pictures has been done and samples run as Mut-ko/ki, Ctl pairs, and then splitting
nitrocellulose to probe multiple enzymes at one time. Bar graphs for each quantitation normalized to Vdac1 (blue is Mut-ko/ki and grey is Ki/wt). * p < .05,
**p < .01. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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To look at whether quantity of enzyme impacted activity, we
measured levels of mRNA by microarray and protein amounts by im-
munoblot. Tables 1 and 2 summarize the mRNA expression results
listing fold changes, Average log2 levels (Avg log2) and p-values for Ctl
liver samples (Avg log2) and the Mut-ko/ki model (Mut-ko/ki Avg
log2). Table 2 also lists the calculated amount of mRNA detected based
on the standard Log2 average levels as reported standardly as mRNA
quantification from microarrays seen in Table 1. Briefly, the Mut-ko/ki
and Ctl had differences of expression of two-fold or more for Fh, Mdh2
and Mmut. More specifically, the Mut-ko/ki compared to the Ctl had
2.07-fold more Fh mRNA detected with a p value of 0.014. On the other
hand, the liver from Ctl sample had 2.3-fold increased expression in
Mdh2 than the Mut-ko/ki, but this difference does not meet the criteria
for a significant p value. Mmut mRNA is significantly different in the
Mut-ko/ki mouse compared to Ctl as is expected given its genotype with
a fold change of −7.41. All other enzymes do not have fold changes
greater than (or less than) 2 as well as non-significant p values.
To determine whether these differences correlate with protein
amounts, we used semi-quantitative immunoblotting as measured by
the Chemdoc system of each TCA cycle protein. Isolated mitochondria
protein levels of Fh (p= .024), Mdh2 (p= .029), Ogdh (p= .02) and
Mmut (p= .003) were significantly decreased in the MMA model
compared to littermate controls (immunoblots in Fig. 2 and quantita-
tion in Table 2).
Next, we measured the activity of individual TCA cycle enzymes
from isolated, partially opened mitochondria. The enzymatic activity
levels of individual TCA members were consistent with protein levels,
whereby activity of Ogdhc was decreased, while there was a trend to a
decrease for Fh and Mdh2 in the Mut-ko/ki mice while all others were
similar to Ctl (Fig. 3, Suppl. Fig. S1–7).
Ogdhc activity is significantly decreased in the Mut-ko/ki mice
compared to Ctl mice (student t-test, p= .037) as was the amount of
protein (p= .02) (Figs. 2, 3, Suppl. Fig. S3, and Table 2). There is no
difference in the RNA quantification for Ogdh of this enzyme (Tables 1
and 2). Unlike Ogdhc, Fh has a lower amount of enzyme activity (Fig. 3
and Table 2), but this does not reach statistical significance (p= .11)
despite its lower enzyme amounts. There is a similar finding for Mdh2
(Fig. 3 and Table 2). Although activity appears decreased as well as
enzyme amount, neither reach statistical significance. The differences
between the Mut-ko/ki mouse model and Ctl appear to be correlated
such that the amount of enzyme activity is consistent with the amount
of enzyme observed for any one particular TCA component (Suppl. Fig.
S8). Thus, even when the same amount of mitochondrial protein is used
(whether for immunoblot or enzyme activity studies) the percentages of
the amount of enzyme present in the whole extract differs between the
Mut-ko/ki mouse model and the Ctl and the activity is consistent with
that amount of enzyme.
Finally, since Mmut forms an anaplerotic reaction which feeds into
the TCA cycle at succinate synthase (Ss), we further performed a multi-
step analysis, whereby we incubated mitochondria with methylma-
lonyl-CoA and examined production of fumarate, requiring the activ-
ities of Mmut, Ss, and Sdh. We found a significant decrease in this
pathway activity in the Mut-ko/ki mice compared to Ctl (p= .017,
Suppl, Fig. 9 and 10). This is the expected result given the deficiency of
Mmut in this model and supports its utility as a model for MMA.
Our results suggest that in this model, there is decreased TCA cycle
function. However, in our hands, this decreased function stems from
decreased protein levels of certain TCA cycle proteins. We interpret our
data to show that decreased protein levels come via regulation at the
protein level, since mRNA abundance in MMA mice and littermate
controls do not always correlate with protein amounts. Thus, we pro-
pose based on this data that loss of Mmut disrupts the TCA metabolon,
resulting in loss of certain TCA cycle proteins and ultimately TCA cycle
disruption.
4. Discussion
Here our interpretation of the evidence says that we can 1) assay the
TCA cycle enzymes in samples prepared from flash frozen liver from
mice (Ctl and Mut-ko/ki) and 2) demonstrate statistical differences in
Table 1
Amounts measured by Clariom S mouse Array (Applied Biosystems) of mRNA
listed in the order of significance by p-value. Fold change (Log2) is also listed
for each of the enzymes including Mmut, Fh, Idh2, Mdh2, Sdha, Cs, Ogdh,
Suclg2, Vdac1.
Gene symbol Mut-ki/ko
Avg (log2)
Ctl
Avg (log2)
Fold change P-val
Mmut 6.59 ± 0.37 9.48± 1.37 −7.41 0.0119⁎
Fh 11.27 ± 0.32 10.22 ± 0.03 2.07 0.0138⁎
Idh2 10.36 ± 0.4 9.51 ± 0.15 1.79 0.0419⁎
Mdh2 7.81 ± 0.76 9.01 ± 0.97 −2.3 0.1196
Sdha 7.22 ± 0.82 7.77 ± 0.01 −1.47 0.2771
Cs 10.29 ± 0.59 10.54±0.47 −1.19 0.5829
Ogdh 9.14 ± 0.76 8.91 ± 0.15 1.17 0.6206
Suclg2 9.82 ± 0.42 9.91 ± 0.66 −1.06 0.8477
Vdac1 9.84 ± 0.54 9.88 ± 0.82 −1.03 0.9402
⁎ p value< .05.
Table 2
Comparison of quantitation of mRNA, protein, and enzyme activity identified for the TCA enzymes measured and Mmut in the Mut-ko/ki and the Ctl mouse liver
samples. In general, protein levels appear to better correlate to enzyme activity than mRNA amounts.
Enzyme Mut-ki/ko
mRNA (Avg log2)
levels
Ki/wt
mRNA (Avg log2)
levels
Mut- ko/ki
ratio with
Ki/wt
mRNA
ratio
Mut-ki/ko
Protein (Amt/
Amt Vdac1)
Ki/wt
Protein
(Amt/Amt
Vdac1)
Mut- ko/ki
ratio with
Ki/wt
Protein ratio
Mut- ko/ki
Enzyme
(nmol* s−1 *
mg−1)
Ki/wt
Enzyme
nmol* s−1 *
mg−1)
Mut-ko/ki
ratio with Ki/
wt
Enzyme ratio
CS 10.29± 0.59 10.54 ± 0.47 0.97 0.96 ± 0.18 1.0 ± 0.12 0.95 68 62 1.1
IDH2(3)
(Idh2)
10.36 ± 0.4 9.51 ± 0.15 1.09 0.75 ± 0.15 1.02 ± 0.22 0.74 43 50 0.87
OGDHc
(Ogdh)
9.14 ± 0.76 8.91 ± 0.15 1.03 0.58⁎ 1.01 0.57 1.2⁎ 1.7 0.67
SCS
(Suclg2)
9.82 ± 0.42 9.91 ± 0.66 0.99 0.95 1.01 0.93 140 130 1.1
SDH (Sdha) 7.22 ± 0.82 7.77 ± 0.01 0.92 0.7 1.04 0.67 15 16 0.91
Fh 11.27 ± 0.32 10.22 ± 0.03 1.1 0.57⁎ 1 0.57 7.8 12 0.67
MDH2 7.81 ± 0.76 9.01 ± 0.97 0.86 0.66⁎ 1 0.66 190 250 0.75
Mut (via SS-
SDH)
6.59 ± 0.37 9.48 ± 1.37 0.69 0.49⁎⁎ 1 0.49 0.293 1.033 0.28
⁎ p < .05.
⁎⁎ p < .01.
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enzyme activity between that of theMut-ko/ki mouse and Ctl for Ogdhc
which appears to be explained by amount of enzyme available. We
observed no statistical differences in the quantity of most TCA enzyme
(excluding Ogdh, Mdh2, and Fh) in the Mut-ko/ki and Ctl samples. In
our hands, Ogdh, Fh, and Mdh2 show significant differences in quantity
in the Mut-ko/ki mouse and Ogdhc also shows this in measured enzy-
matic rate. Increased statistical power from a larger number of samples
may have allowed demonstration of a significant decrease in Fh and
Mdh2 activity as well, since the difference in the amount of protein was
small and the difference in activity would be expected to be small as
well.
MMA's long-term complications are hypothesized to be a result of
the accumulation of toxic intermediates (e.g. propionyl-CoA, methyl-
malonyl-CoA, 3-hydroxypropionate and 2-methycitrate, among others)
which lead to abnormalities in enzyme functions resulting in decreased
activity. The TCA dehydrogenases are a particularly concerning direct
target [10,36–38]. In our study, we note some variation in enzyme
function, but this variation correlates with the amount of enzyme ob-
served (Fig. 2, Fig. 3, and Table 2). Here we see decreased OGDH ac-
tivity and amounts, this could greatly impact the turnover in the TCA
cycle since OGDH is a known regulator as well as would be a choke-
point.
Several studies have implicated the toxic intermediates from
dysfunctional Mmut causing dehydrogenase dysfunction [10,19,39].
The Mut-ko/ki mice used here have elevated markers of disease include
methylmalonate and propionylcarnitine to acetylcarnitine ratios which
are associated with elevated propionyl-CoA [26] and so we expect that
if such an inhibition of enzyme activity could be observed, we should
have been able to detect it in this model. In our samples, the dehy-
drogenases (Ogdh, Idh2/3, Mdh2, and Sdh) do not have greater in-
hibition in theMut-ko/ki mouse samples than other enzymes in the TCA
cycle when activity is corrected for enzyme availability (Suppl. Fig.S8).
This provides evidence against the toxic inhibitor hypothesis. However,
it does not address whether amount of enzyme available for function is
impacted by these toxins or whether higher amounts of these toxins
would change this result.
There are some limitations to our study. Of note, we choose to not
establish the aconitase assay since its iron‑sulfur complex becomes
dissociated with freezing [40] and felt that this assay was less in-
formative at baseline. We acknowledge that these are flash frozen
samples whereas fresh samples may potentially be better for assays
since they are less likely to be impacted by freezing, but the goal was to
demonstrate activity using this model so that other samples (e.g. human
flash-frozen liver samples) which are not typically available in fresh
states can be analyzed.
We recognize that fasting versus fed state can impact TCA enzyme
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Fig. 3. Enzyme activity measured for each of the TCA enzymes assayed. For each graph, the experimental control (distilled water or dW, black, added instead of
substrate), Mut-ko/ki (blue) and Ki/wt (grey) are listed. A. Cs activity (pmol/s per 5 μg mitochondrial protein), B. Idh2/3 activity (pmol/s per 30 μg mitochondrial
protein), C. Ogdh activity (pmol/s per 30 μg mitochondrial protein). D. Succinyl-CoA synthetase activity (pmol/s per 20 μg mitochondrial protein), E. Sdh activity
(pmol/s per 30 μg mitochondrial protein), F. Fh activity (pmol/s per 30 μg mitochondrial protein), H. Mdh2 activity (pmol/s per 30 μg mitochondrial protein). *
p < .05. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
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activity, but here we harvested the organisms from Ctl and Mut-ko/ki
mice at the same time under the same conditions (fed state). Further
studies are necessary to explore differences in quantitation under dif-
ferent conditions. There were no differences detected between female
and male mice for enzyme activity in preliminary studies, here all are
female mice.
In this paper, we have assayed TCA enzymes from flash frozen
material from Ctl and Mut-ko/ki livers proving that this can be done on
other flash frozen samples. We observed that TCA enzyme activity does
vary for some enzymes, but this variation correlates with enzyme
quantity. Finally, for Ogdh, the enzyme with the most different activity
between the Mut-ko/ki and Ctl tissues, we have demonstrated that the
protein quantitation differences are not reflected in the level of tran-
scription. This suggests either changes in post-transcriptional proces-
sing or increased degradation of enzyme. Other enzymes in our study
have differences at the level of transcription which reflect in differences
in protein amounts.
These studies help clarify how complicated TCA cycle regulation is
with differing levels of enzymes from the same amount of mitochon-
drial protein in the extract. This impacts the development of therapies
for MMA, since the decreases in key elements of energy production may
affect efforts at anaplerotic manipulation. These studies support the
observation that MMA is a complex enzymatic phenotype with both
upstream and downstream consequences.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ymgme.2019.10.007.
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